Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$71.58 - $87.29 $487,459 - $594,444
6,810 New
6,810 $498,000
Q3 2023

Nov 02, 2023

BUY
$73.94 - $80.67 $455,470 - $496,927
6,160 New
6,160 $461,000
Q4 2022

Feb 10, 2023

BUY
$62.32 - $89.47 $65,436 - $93,943
1,050 Added 19.85%
6,340 $544,000
Q3 2022

Nov 07, 2022

SELL
$59.54 - $68.01 $149,445 - $170,705
-2,510 Reduced 32.18%
5,290 $326,000
Q2 2022

Aug 02, 2022

SELL
$57.72 - $65.01 $43,867 - $49,407
-760 Reduced 8.88%
7,800 $482,000
Q1 2022

May 11, 2022

BUY
$57.92 - $72.58 $495,795 - $621,284
8,560 New
8,560 $509,000
Q3 2021

Oct 29, 2021

SELL
$67.69 - $73.03 $284,298 - $306,726
-4,200 Closed
0 $0
Q2 2021

Aug 10, 2021

BUY
$63.47 - $69.35 $266,574 - $291,270
4,200 New
4,200 $289,000
Q1 2021

May 07, 2021

SELL
$60.0 - $68.46 $621,600 - $709,245
-10,360 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$56.65 - $64.55 $83,275 - $94,888
1,470 Added 16.54%
10,360 $604,000
Q3 2020

Nov 02, 2020

BUY
$62.1 - $78.08 $552,069 - $694,131
8,890 New
8,890 $562,000
Q2 2020

Aug 05, 2020

SELL
$72.34 - $84.0 $780,548 - $906,360
-10,790 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$62.63 - $80.22 $1.16 Million - $1.48 Million
-18,483 Reduced 63.14%
10,790 $807,000
Q4 2019

Feb 13, 2020

SELL
$61.62 - $67.78 $428,259 - $471,071
-6,950 Reduced 19.19%
29,273 $1.9 Million
Q3 2019

Nov 13, 2019

BUY
$62.51 - $69.0 $466,137 - $514,533
7,457 Added 25.92%
36,223 $2.3 Million
Q2 2019

Aug 09, 2019

BUY
$61.87 - $69.38 $876,450 - $982,837
14,166 Added 97.03%
28,766 $1.94 Million
Q1 2019

May 07, 2019

BUY
$62.53 - $70.05 $125,060 - $140,100
2,000 Added 15.87%
14,600 $949,000
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $762,804 - $995,400
12,600 New
12,600 $788,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Asahi Life Asset Management Co., Ltd. Portfolio

Follow Asahi Life Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Asahi Life Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Asahi Life Asset Management Co., Ltd. with notifications on news.